Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2018

01-10-2018 | Review

Breast cancer and its impact in male transsexuals

Authors: Dejan Nikolić, Miroslav Granić, Nebojša Ivanović, Darko Zdravković, Aleksandra Nikolić, Violeta Stanimirović, Marija Zdravković, Srdjan Dikić, Marko Nikolić, Miroslav Djordjević

Published in: Breast Cancer Research and Treatment | Issue 3/2018

Login to get access

Abstract

Introduction

Lesbian, gay, and bisexuals have unique healthcare needs. Breast cancer is leading cancer in women, worldwide, accounting for 25% of all cases. Annual incidence rates increased significantly in all countries and age groups. The occurrence of breast cancer is rare in transgender population. As they have very limited access to medical care, it is much less likely to pursue breast cancer screening than in other individuals not identified as transgender.

Review of the cases from literature

Up to date, only 13 cases of the breast cancer transsexuals (female to male) have been reported in six published papers worldwide. Histological examination of the breast tumor in female-to-male transgender showed progesterone/estrogen-positive invasive ductal carcinoma.

Discussion

Gender identity describes a person’s inherent sense of being a woman, man, or of neither gender, whereas sexual orientation refers to how people identify their physical and emotional attraction to others. Gender reassignment surgery, as series of complex surgical genital and non-genital procedures, is recognized as the most effective treatment for patients with gender dysphoria. The two main principles of hormone therapy for transgender patients are to reduce endogenous hormone levels and their associated sex characteristics and replace them with hormones of the preferred sex. Breast cancer infrequently occurs in transgender patients. Even breast core biopsies can be difficult for interpreting after changes in breast tissue in female-to-male transsexuals following gender reassignment.

Conclusion

Reviewing the literature, so many different data concerning probability of breast cancer in sexual minority can be found. Breast cancer screening program should be offered to all transgender individuals according to national guidelines. Very important is to take into consideration a transgender person’s natal and surgical anatomy, unique clinical concerns for depression and anxiety, risk of suicide together with risk factors including experiences of harassment or physical or sexual violence, low education level, and unemployment. Understanding the need for mammography in these often marginalized groups is very important in addressing breast cancer disparities despite differences in insurance coverage in some countries and greater concern for the cancer of the breast in residual breast tissue. The best screening rule, ever, for breast cancer in male transsexuals and other similar population should be, besides surgical history and hormonal status, “Screen Now, Screen Regularly and Screen What You Have.”
Literature
1.
go back to reference McNamara M, et NG H (2016) Best practices in LGBT care: A guide for primary care physicians. Clev Clin J Med 83(7):533–540CrossRef McNamara M, et NG H (2016) Best practices in LGBT care: A guide for primary care physicians. Clev Clin J Med 83(7):533–540CrossRef
2.
go back to reference ”World Cancer Report” (2014) World Health Organization. 2014. pp. Chapter 1.1. ISBN 92-832-0429-8 ”World Cancer Report” (2014) World Health Organization. 2014. pp. Chapter 1.1. ISBN 92-832-0429-8
3.
go back to reference Nikolic DV, Djordjevic ML, Granic M, Nikolic AT, Stanimirovic VV, Zdravkovic D, Jelic S (2012) Importance of revealing a rare case of breast cancer in a female to male transsexual after bilateral mastectomy. World J Surg Oncol 10:280CrossRefPubMedPubMedCentral Nikolic DV, Djordjevic ML, Granic M, Nikolic AT, Stanimirovic VV, Zdravkovic D, Jelic S (2012) Importance of revealing a rare case of breast cancer in a female to male transsexual after bilateral mastectomy. World J Surg Oncol 10:280CrossRefPubMedPubMedCentral
4.
go back to reference World Cancer Report (2008) International Agency for Research on Cancer World Cancer Report (2008) International Agency for Research on Cancer
5.
go back to reference Male Breast Cancer Treatment (2014) National Cancer Institute Male Breast Cancer Treatment (2014) National Cancer Institute
6.
go back to reference Dimitrova N, Znaor A, Agius D, Eser S, Sekerija M, Ryzhov A, Primic-Žakelj M, Coebergh JW, SEE + Working Group (2017) Breast cancer in South-Eastern European countries since 2000. Rising incidence and decreasing mortality at young and middle ages. Eur J Cancer 83:43–55 Dimitrova N, Znaor A, Agius D, Eser S, Sekerija M, Ryzhov A, Primic-Žakelj M, Coebergh JW, SEE + Working Group (2017) Breast cancer in South-Eastern European countries since 2000. Rising incidence and decreasing mortality at young and middle ages. Eur J Cancer 83:43–55
7.
go back to reference Willemsen HW, Kaas R, Peterse JH, Rutgers EJ (1998) Breast carcinoma in residual breast tissue after prophylactic bilateral subcutaneous mastectomy. Eur J Surg Oncol 24(4):331–332CrossRefPubMed Willemsen HW, Kaas R, Peterse JH, Rutgers EJ (1998) Breast carcinoma in residual breast tissue after prophylactic bilateral subcutaneous mastectomy. Eur J Surg Oncol 24(4):331–332CrossRefPubMed
8.
go back to reference Gooren LJ (2014) Management of female-to-male transgender persons: medical and surgical management, life expectancy. Curr Opin Endocrinol Diabetes Obes 21(3):233–238CrossRefPubMed Gooren LJ (2014) Management of female-to-male transgender persons: medical and surgical management, life expectancy. Curr Opin Endocrinol Diabetes Obes 21(3):233–238CrossRefPubMed
9.
go back to reference Ramos Boyero M (2008) Skin-sparing mastectomy: an alternative to conventional mastectomy in breast cancer. Cir Esp 84(4):181–187CrossRefPubMed Ramos Boyero M (2008) Skin-sparing mastectomy: an alternative to conventional mastectomy in breast cancer. Cir Esp 84(4):181–187CrossRefPubMed
11.
go back to reference Pivo S, Montes J, Schwartz S, Chun J, Kiely D, Hazen A, Schnabel F (2017) Breast cancer risk assessment and screening in transgender patients. Clin Breast Cancer 17(5): e225–e227CrossRefPubMed Pivo S, Montes J, Schwartz S, Chun J, Kiely D, Hazen A, Schnabel F (2017) Breast cancer risk assessment and screening in transgender patients. Clin Breast Cancer 17(5): e225–e227CrossRefPubMed
12.
go back to reference Burcombe RJ, Makris A, Pirtam M et al (2003) Breast cancer after bilateral subcutaneous mastectomy in female to male case. Breast 12:290–293CrossRefPubMed Burcombe RJ, Makris A, Pirtam M et al (2003) Breast cancer after bilateral subcutaneous mastectomy in female to male case. Breast 12:290–293CrossRefPubMed
13.
go back to reference Bevers TB (2010) Breast cancer prevention. an update of the STAR trial. Curr Treat Options Oncol 11:66–69CrossRefPubMed Bevers TB (2010) Breast cancer prevention. an update of the STAR trial. Curr Treat Options Oncol 11:66–69CrossRefPubMed
14.
go back to reference Brown GR, Jones KT. Incidence of breast cancer in a cohort of 5,135 transgender veterans. Breast Cancer Res Treat 149(1):191–198 Brown GR, Jones KT. Incidence of breast cancer in a cohort of 5,135 transgender veterans. Breast Cancer Res Treat 149(1):191–198
15.
go back to reference Bazzi AR, Whorms DS, King DS et al (2015) Adherence to mammography screening guidelines among transgender persons and sexual minority women. Am J Public Health 105:2356–2358CrossRefPubMedPubMedCentral Bazzi AR, Whorms DS, King DS et al (2015) Adherence to mammography screening guidelines among transgender persons and sexual minority women. Am J Public Health 105:2356–2358CrossRefPubMedPubMedCentral
16.
go back to reference Burcombe RJ, Makris A, Pittam M, Finer N (2003) Breast cancer after bilateral subcutaneous mastectomy in a female to male transsexual. Breast 12(4):290–293CrossRefPubMed Burcombe RJ, Makris A, Pittam M, Finer N (2003) Breast cancer after bilateral subcutaneous mastectomy in a female to male transsexual. Breast 12(4):290–293CrossRefPubMed
17.
go back to reference Shao T, Grossbard LM, Klein P (2011) Breast cancer in Female to male transsexuals: two cases with a review of physiology and management. Clin Breast Cancer 11(6):417–419CrossRefPubMed Shao T, Grossbard LM, Klein P (2011) Breast cancer in Female to male transsexuals: two cases with a review of physiology and management. Clin Breast Cancer 11(6):417–419CrossRefPubMed
18.
go back to reference Gooren LJ, van Trotsenburg MA, van Diest GiltayEj (2013) PJ.: Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med 10(12):3129–3134CrossRefPubMed Gooren LJ, van Trotsenburg MA, van Diest GiltayEj (2013) PJ.: Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med 10(12):3129–3134CrossRefPubMed
19.
go back to reference Kotsopoulos J, Steve A (2017) Androgens and breast cancer. J Sex Med 14(5):741–746CrossRef Kotsopoulos J, Steve A (2017) Androgens and breast cancer. J Sex Med 14(5):741–746CrossRef
20.
go back to reference Spack NP (2013) Management of transgenderism. JAMA 309:474–484 Spack NP (2013) Management of transgenderism. JAMA 309:474–484
22.
go back to reference Selvaggi G, Bellringer J (2011) Gender reassignment surgery: an overview. Nat Rev Urol 8(5):274–282CrossRefPubMed Selvaggi G, Bellringer J (2011) Gender reassignment surgery: an overview. Nat Rev Urol 8(5):274–282CrossRefPubMed
23.
go back to reference Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA et al (2009) Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 94:3132–3133CrossRefPubMed Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA et al (2009) Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 94:3132–3133CrossRefPubMed
25.
go back to reference Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. New Engl J Med 354:270–282CrossRefPubMed Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. New Engl J Med 354:270–282CrossRefPubMed
26.
go back to reference Secreto G, Zumoff B (2012) Role of androgen excess in the development of estrogen receptor-positive and estrogen receptor-negative breast cancer. Anticancer Res 32:3223–3228PubMed Secreto G, Zumoff B (2012) Role of androgen excess in the development of estrogen receptor-positive and estrogen receptor-negative breast cancer. Anticancer Res 32:3223–3228PubMed
27.
go back to reference Hankinson SE et al (1998) Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 90(17):1292–1299CrossRefPubMed Hankinson SE et al (1998) Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 90(17):1292–1299CrossRefPubMed
28.
go back to reference Veronesi U, Pizzocaro G (1968) Breast cancer in women subsequent to cystic disease of the breast. Surg Gynecol Obstet 126(3):529–532PubMed Veronesi U, Pizzocaro G (1968) Breast cancer in women subsequent to cystic disease of the breast. Surg Gynecol Obstet 126(3):529–532PubMed
29.
go back to reference Secreto G et al (1984) Increased androgenic activity and breast cancer risk in premenopausal women. Cancer Res 44(12 Pt 1):5902–5905PubMed Secreto G et al (1984) Increased androgenic activity and breast cancer risk in premenopausal women. Cancer Res 44(12 Pt 1):5902–5905PubMed
30.
go back to reference James RE, Lukanova A, Dossus L, Becker S, Rinaldi S, Tjonneland A et al (2011) Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study. Cancer Prev Res 4:1626–1635CrossRef James RE, Lukanova A, Dossus L, Becker S, Rinaldi S, Tjonneland A et al (2011) Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study. Cancer Prev Res 4:1626–1635CrossRef
31.
go back to reference Diaz-Chico N, German Rodriguez B, Gonazalez F, Ramirez A, Bilbao R, Cabrera de Lekon C, et al (2007) Androgens and androgen receptors in breast cancer. J Steroid Bichem Mol Biol 105:1–15CrossRef Diaz-Chico N, German Rodriguez B, Gonazalez F, Ramirez A, Bilbao R, Cabrera de Lekon C, et al (2007) Androgens and androgen receptors in breast cancer. J Steroid Bichem Mol Biol 105:1–15CrossRef
32.
go back to reference Adly L, Hill D, Sherman ME, Sturgeon SR, Fears T, Mies C et al (2006) Serum concentrations of estrogens, sex hormone-binding globulin, and androgens and risk of breast cancer in postmenopausal women. Int J Cancer 119:2702–2707CrossRef Adly L, Hill D, Sherman ME, Sturgeon SR, Fears T, Mies C et al (2006) Serum concentrations of estrogens, sex hormone-binding globulin, and androgens and risk of breast cancer in postmenopausal women. Int J Cancer 119:2702–2707CrossRef
33.
go back to reference Danforth KN, Eliassen AH, Tworoger SS, Missmer SA, Barbieri PL, Rosner BA et al (2010) The association of plasma androgen levels with breast, ovarian and endometrial cancer risk among postmenopausal women. Int J Cancer 126:199–207CrossRefPubMedPubMedCentral Danforth KN, Eliassen AH, Tworoger SS, Missmer SA, Barbieri PL, Rosner BA et al (2010) The association of plasma androgen levels with breast, ovarian and endometrial cancer risk among postmenopausal women. Int J Cancer 126:199–207CrossRefPubMedPubMedCentral
34.
go back to reference Mathwe H, Hamid B (2013) Context is everything:an unusual breast core biopsy case. Int J Surg Pathol 21(5):502–503CrossRef Mathwe H, Hamid B (2013) Context is everything:an unusual breast core biopsy case. Int J Surg Pathol 21(5):502–503CrossRef
35.
go back to reference Hartmann LC et al (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. New Engl J Med 340(2):77–84CrossRefPubMed Hartmann LC et al (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. New Engl J Med 340(2):77–84CrossRefPubMed
36.
go back to reference Meads C, Moore D (2013) Breast cancer in lesbians and bisexual women: systematic review of incidence, prevalence and risk studies. BMC Public health 13:1127CrossRefPubMedPubMedCentral Meads C, Moore D (2013) Breast cancer in lesbians and bisexual women: systematic review of incidence, prevalence and risk studies. BMC Public health 13:1127CrossRefPubMedPubMedCentral
37.
go back to reference Mays VM, Cochran SD (2001) Mental health correlates of perceived discrimination among lesbian, gay, and bisexual adults in the United States. Am J Public Health 91:1869–1875CrossRefPubMedPubMedCentral Mays VM, Cochran SD (2001) Mental health correlates of perceived discrimination among lesbian, gay, and bisexual adults in the United States. Am J Public Health 91:1869–1875CrossRefPubMedPubMedCentral
38.
go back to reference Center of Excellence for Transgender Health (2011) Primary care protocol for transgender patient care. Department of Family and Community Medicine, University of California, San Francisco Center of Excellence for Transgender Health (2011) Primary care protocol for transgender patient care. Department of Family and Community Medicine, University of California, San Francisco
39.
go back to reference Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA et al (2009) Endocrine treatment of trnassexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 94(9):3132–3154CrossRefPubMed Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA et al (2009) Endocrine treatment of trnassexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 94(9):3132–3154CrossRefPubMed
40.
go back to reference Sherbourne Health Center (2009) Guidelines and protocols for comprehensive primary care for trans clients. Sherbourne Health Center, Toronto Sherbourne Health Center (2009) Guidelines and protocols for comprehensive primary care for trans clients. Sherbourne Health Center, Toronto
41.
go back to reference Eldar S, Meguid MM, Beatty JD (1984) Cancer of the breast after prophylactic subcutaneous mastectomy. Am J Surg 148(5):692–693CrossRefPubMed Eldar S, Meguid MM, Beatty JD (1984) Cancer of the breast after prophylactic subcutaneous mastectomy. Am J Surg 148(5):692–693CrossRefPubMed
42.
go back to reference Goodnight JE, Quagliana JM, Morton DL (1984) Failure of subcutaneous mastectomy to prevent the development of breast cancer. J SurgOncol 26(3):198–201 Goodnight JE, Quagliana JM, Morton DL (1984) Failure of subcutaneous mastectomy to prevent the development of breast cancer. J SurgOncol 26(3):198–201
43.
go back to reference Ziegler LD, Kroll SS (1991) Primary breast cancer after prophylactic mastectomy [clinical conference]. Am J Clin Oncol 14(5):451–454PubMed Ziegler LD, Kroll SS (1991) Primary breast cancer after prophylactic mastectomy [clinical conference]. Am J Clin Oncol 14(5):451–454PubMed
44.
go back to reference Bowers DG, Radlauer CB (1969) Breast cancer after prophylactic subcutaneous mastectomies and reconstruction with silastic prostheses. Plast Reconstr Surg 44(6):541–544CrossRefPubMed Bowers DG, Radlauer CB (1969) Breast cancer after prophylactic subcutaneous mastectomies and reconstruction with silastic prostheses. Plast Reconstr Surg 44(6):541–544CrossRefPubMed
45.
go back to reference Holleb AI, Montgomery R, Farrow JH (1965) The hazard of incomplete simple mastectomy. SurgGynecol Obstet 121(4):819–822 Holleb AI, Montgomery R, Farrow JH (1965) The hazard of incomplete simple mastectomy. SurgGynecol Obstet 121(4):819–822
46.
go back to reference Robertson Bazzi A, Whorms SD, King SD, Potter J (2015) Adherence to mamography screening guidelines among transgender persons and sexual minorities. Am J Public Health 105(11):2356–2358CrossRef Robertson Bazzi A, Whorms SD, King SD, Potter J (2015) Adherence to mamography screening guidelines among transgender persons and sexual minorities. Am J Public Health 105(11):2356–2358CrossRef
Metadata
Title
Breast cancer and its impact in male transsexuals
Authors
Dejan Nikolić
Miroslav Granić
Nebojša Ivanović
Darko Zdravković
Aleksandra Nikolić
Violeta Stanimirović
Marija Zdravković
Srdjan Dikić
Marko Nikolić
Miroslav Djordjević
Publication date
01-10-2018
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4875-y

Other articles of this Issue 3/2018

Breast Cancer Research and Treatment 3/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine